MedPath

Fetal Abdominal Subcutaneous Tissue Thickness in Prediction of Fetal Weight in Term Pregnant Women

Not yet recruiting
Conditions
Fetal Weight
Ultrasound
Registration Number
NCT06456957
Lead Sponsor
Assiut University
Brief Summary

Fetal Abdominal subcutaneous tissue thickness (FASTT) can be easily measured during the routine ultrasound examination of pregnant women. Numerous reports have shown FASTT measurement to be a good way of evaluating subcutaneous fat tissue.

However, to the best of our knowledge, no studies have investigated the association of FASTT with abnormal fetal growth in nondiabetic. For this reason, in this study we evaluated whether FASTT can predict birth weight or diagnose LGA and/or LBW infants in the third trimester.

Detailed Description

The fetal weight assessment by ultrasound is essential in obstetric practice to determine the labor mode, time, and management. It is an important to detect fetal growth abnormalities such as small for gestational age (SGA), fetal growth restriction (FGR) and large for gestational age (LGA) fetuses; thus, it could help in decreasing the perinatal morbidity and mortality rates \[1\]. Many methods have been introduced to estimate the weight in utero, and many studies have evaluated their effectiveness to detect the most accurate method \[2\]. Abnormal fetal growth can be diagnosed by ultrasound. Conventional ultrasonic measurements, such as estimated fetal weight (EFW) and abdominal circumference (AC) can distinguish LGA/macrosomia or LBW infants. Many studies have demonstrated that expected fetal weight (EFW) by the traditional techniques is not a reliable indicator of growth abnormalities; consequently several other sono graphic measurements have been proposed \[3\]. Ultrasound has its limitations despite the use of more than 50 different formulae to estimate fetal weight as their performance is poor at the extremes of fetal weight. There has been emerging interest in studying fetal soft tissue measurements to improve the detection of growth abnormalities \[4\].

Fetal Abdominal subcutaneous tissue thickness (FASTT) can be easily measured during the routine ultrasound examination of pregnant women. Numerous reports have shown FASTT measurement to be a good way of evaluating subcutaneous fat tissue \[5\].Furthermore, some researchers have investigated links between FASTT and diabetes \[6\].

However, to the best of our knowledge, no studies have investigated the association of FASTT with abnormal fetal growth in nondiabetic. For this reason, in this study we evaluated whether FASTT can predict birth weight or diagnose LGA and/or LBW infants in the third trimester.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
240
Inclusion Criteria
  1. Singleton pregnancy.
  2. Gestational age between 37-42 weeks.
  3. Accepting to be included in the study
Exclusion Criteria
  1. Pre-gestational diabetes and gestational diabetes.
  2. Other medical disorder as hypertensive disorder during pregnancy, cardiac diseases.
  3. Congenital fetal malformation affecting birth weight or affecting clavicle.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sensitivity of measuring Fetal Abdominal Subcutaneous Tissue Thickness37-40 weeks gestation

To evaluate sensitivity of measuring Fetal Abdominal Subcutaneous Tissue Thickness compared to Hadlock formula IV in Prediction of Fetal Weight in Term non-diabetic Pregnant Women in 3rd trimester.

Secondary Outcome Measures
NameTimeMethod
Gestational age at the time of delivery1 week from recruitment

detection of gestational age at the time of delivery

Mode of delivery.37-40 weeks gestation

Vaginal delivery or cesarean section

Neonatal Apgar scoreat the time of delivery

Measure Apgar score for the newborn at 1 minute and 5 minutes

Neonatal need for NICUat the time of delivery

Need for admission of neonate at NICU and Number of days if admitted

Neonatal birth weightat the time of delivery

Measure of Neonatal weight in grams

© Copyright 2025. All Rights Reserved by MedPath